{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable.","groupId":"OG000","lowerLimit":"3.7","upperLimit":"NA","value":"9.7"},{"comment":"Not estimable.","groupId":"OG001","value":"NA"},{"comment":"Not estimable.","groupId":"OG002","lowerLimit":"5.8","upperLimit":"NA","value":"21.8"},{"comment":"Not estimable.","groupId":"OG003","lowerLimit":"3.8","upperLimit":"NA","value":"13.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"7"}],"units":"Participants"}],"title":"RECIST v1.1"},{"categories":[{"measurements":[{"comment":"Not estimable.","groupId":"OG000","lowerLimit":"4.1","upperLimit":"NA","value":"13.0"},{"comment":"Not estimable.","groupId":"OG001","value":"NA"},{"comment":"Not estimable.","groupId":"OG002","lowerLimit":"6.8","upperLimit":"NA","value":"22.1"},{"comment":"Not estimable.","groupId":"OG003","lowerLimit":"4.6","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"8"}],"units":"Participants"}],"title":"irRECIST"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"8"}],"units":"Participants"}],"description":"DOR was defined as the time from start date (which was the date of first documentation of PR or CR) to date of first documentation of objective progression or death. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. Objective progression was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. As this outcome measure was a secondary endpoint defined in the protocol to investigate preliminary signal of efficacy, the results were analyzed and are reported for Part 1 dose-escalation groups combined to provide more statistically meaningful results, instead of results analyzed by dose level with very limited number of participants in each group.","dispersionType":"95% Confidence Interval","groups":[{"description":"This was a combined group of PF-06801591 0.5, 1, 3, and 10 mg/kg (IV) in Part 1. Participants received PF-06801591 0.5, 1, 3, or 10 mg/kg IV every 3 weeks for 21-day cycles. (up to a maximum of 233 weeks).","id":"OG000","title":"Part 1: PF-06801591 0.5-10 mg/kg (Intravenously [IV])"},{"description":"Participants received PF-06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 419 days)","id":"OG001","title":"Part 1: PF-06801591 300 mg (Subcutaneously [SC])"},{"description":"Participants with NSCLC received PF-06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 851 days)","id":"OG002","title":"Part 2: PF-06801591 300 mg (SC) for NSCLC"},{"description":"Participants with UC received PF- 06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 841 days)","id":"OG003","title":"Part 2: PF-06801591 300 mg (SC) for UC"}],"paramType":"MEDIAN","populationDescription":"Analysis population included all the randomized participants who received at least 1 dose of study medication, had measurable disease baseline assessment (within 28 days prior to study entry) and at least 1 post baseline assessment or disease progression, global deterioration of health status, or death. DOR was only applicable to those participants with an objective response.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of treatment (maximum of 1606 days)","title":"Duration of Response (DOR) Based on RECIST Version 1.1 and irRECIST - Part 1 and Part 2","type":"SECONDARY","unitOfMeasure":"Months"}